UBT251
Sponsors
The United Bio-Technology (Hengqin) Co., Ltd., Novo Nordisk A/S
Conditions
Chronic Kidney DiseaseDiabetes Mellitus, Type 2Metabolic Dysfunction-associated Steatohepatitis (MASH)ObesityObesity &Amp; OverweightOverweight
Phase 1
A Research Study Looking Into How UBT251 Works With Birth Control Tablets and Emptying of the Stomach in Women With Excess Body Weight Not Able to Become Pregnant
Not yet recruitingNCT07710729
Start: 2026-07-17End: 2027-04-27Target: 40Updated: 2026-07-17
A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood of Participants With Excess Body Weight
Not yet recruitingNCT07710768
Start: 2026-07-15End: 2027-04-07Target: 44Updated: 2026-07-17
Phase 2
UBT251 Injection Phase II Clinical Study (CKD)
RecruitingNCT07134335
Start: 2025-09-01End: 2030-07-11Target: 180Updated: 2025-11-25
A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)
RecruitingNCT07145151
Start: 2025-09-30End: 2027-08-31Target: 156Updated: 2025-11-20
A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity
RecruitingNCT07395687
Start: 2026-02-02End: 2027-02-18Target: 333Updated: 2026-04-21
A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes
RecruitingNCT07668388
Start: 2026-06-22End: 2027-11-15Target: 300Updated: 2026-07-14